Given the fact that M2 macrophages and some subsets of hematological cancers and stem cell populations in solid tumors rely more on OXPHOS than other metabolic pathways for biosynthetic and bioenergetic demands, selective blockade of OXPHOS (281, 284) may be synergistic together with anti-CD47 therapy, in both achieving direct eradication of OXPHOS-dependent tumor cells and reshaping the TME through elimination of protumorigenic, OXPHOS-dependent M2 macrophages. The gene discussed is CD47; the disease is neoplasm.